240 related articles for article (PubMed ID: 37903369)
1. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou GN; Berry K; Rajeevan N; Li Y; Mutalik P; Yan L; Bui D; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Bajema KL
Ann Intern Med; 2023 Nov; 176(11):1486-1497. PubMed ID: 37903369
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
medRxiv; 2022 Dec; ():. PubMed ID: 36561190
[TBL] [Abstract][Full Text] [Related]
4. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
8. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
12. Anti-SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023.
Yan L; Streja E; Li Y; Rajeevan N; Rowneki M; Berry K; Hynes DM; Cunningham F; Huang GD; Aslan M; Ioannou GN; Bajema KL
JAMA Netw Open; 2023 Aug; 6(8):e2331249. PubMed ID: 37651140
[TBL] [Abstract][Full Text] [Related]
13. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
14. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
[TBL] [Abstract][Full Text] [Related]
16. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.
Xie Y; Choi T; Al-Aly Z
JAMA Intern Med; 2023 Jun; 183(6):554-564. PubMed ID: 36951829
[TBL] [Abstract][Full Text] [Related]
17. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation.
Yan L; Bui D; Li Y; Rajeevan N; Rowneki M; Berry K; Argraves S; Huang Y; Hynes DM; Cunningham F; Huang GD; Aslan M; Ioannou GN; Bajema KL
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38864601
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
[TBL] [Abstract][Full Text] [Related]
19. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]